02:22 , Apr 5, 2019 |  BC Innovations  |  Tools & Techniques

Second shot for shRNA

Having long been demoted to tool compound status, shRNA is gaining renewed attention as a therapeutic modality by offering a simpler path to creating next-generation cell therapies than gene editing. Celyad has jumped in, using...
04:20 , Dec 21, 2018 |  BC Innovations  |  Product R&D

Cell therapies seek solid ground

To make cell therapies work in solid tumors, drug companies will have to either master combination therapies or figure out how to make their treatments trigger broad immune responses that extend beyond the antigen specificity...
18:06 , Oct 19, 2018 |  BC Week In Review  |  Company News

Xyphos, Parker Institute steer next-gen Car T therapies into solid tumors

Xyphos Biosciences Inc. (South San Francisco, Calif.) will partner with the Parker Institute for Cancer Immunotherapy to develop CAR Ts using Xyphos' convertible CAR platform. Xyphos President and CEO Jim Knighton told BioCentury the research...
00:36 , Oct 19, 2018 |  BC Innovations  |  Tools & Techniques

Allogeneic CARs on the horizon

With the first generation of autologous, personalized CAR T cell therapies on the market, the field is turning to allogeneic technologies to provide better scale and lower costs. But drug makers are learning that as...
14:01 , Oct 18, 2018 |  BC Extra  |  Company News

Xyphos, Parker Institute steer next-gen CAR T therapies into solid tumors

Xyphos Biosciences Inc. (South San Francisco, Calif.) will partner with the Parker Institute for Cancer Immunotherapy to develop CAR Ts using Xyphos' convertible CAR platform. Xyphos President and CEO Jim Knighton told BioCentury the research...
20:08 , Aug 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Multiple myeloma (MM) Cell culture and mouse studies suggest a bispecific antibody against SLAMF7 and NKG2D could help treat SLAMF7-expressing MM. The bispecific antibody consists of a single-chain variable fragment (scFv) targeting SLAMF7 expressed...
01:36 , Jun 8, 2018 |  BC Innovations  |  Tools & Techniques

NK cell check-in

Until recently, there’s been scarce overlap between the NK cell field and the world of checkpoint inhibitors, with the former focused on cell therapies to kill tumor cells directly and the latter on relieving immune...
20:38 , May 17, 2018 |  BC Innovations  |  Emerging Company Profile

Beyond B cells

PureTech Health plc subsidiary Vor Biopharma Inc. plans to combine CAR T therapies with hematopoietic stem cells modified to go unrecognized by CAR Ts. The approach could increase the types of immune cells that can...
18:54 , Mar 15, 2018 |  BC Innovations  |  Product R&D

Engineered to kill

Nkarta Inc. is betting that boosting NK cells’ intrinsic ability to discriminate between cancer and healthy cells will increase their efficacy as anti-cancer agents and lower their risk of toxicity compared with the more common...
02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...